Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a hypertension drug that requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan) would earn 30 percent patient share according to surveyed U.S. cardiologists. Similarly, in Europe, such an agent would earn comparable patient share of 25 percent according to surveyed European cardiologists. These patient shares are significantly higher than Diovan/Tareg's current patient share (6.1%) and are higher than the patient share achieved by any current hypertension drug.

"In the crowded hypertension market, 25 to 30 percent patient shares are unlikely reached without any evidence of long-term clinical benefit. However, the magnitude of these estimates indicate cardiologists' concern about patient compliance to therapy and their desire for a novel drug that requires less-frequent dosing than Diovan/Tareg, as long as this agent has similar cardioprotective effects as Diovan/Tareg," stated Decision Resources Therapeutic Area Director Nikhil Mehta, M.Eng.

The new report entitled Hypertension: Among Fixed-Dose Combination Agents, AIIRA/CCBs Stand Out for Their Superior Efficacy and Safety also finds that the fixed-dose combination telmisartan/amlodipine will earn Decision Resources' proprietary clinical gold standard status for hypertension in 2013 and through 2018 following its approval for the disease. Telmisartan/ amlodipine has competitive advantages over other emerging therapies because it combines an effective angiotensin II receptor antagonist (AIIRA) -- telmisartan -- with a calcium-channel blocker (CCB) -- amlodipine. Combination of an AIIRA and a CCB provides superior efficacy and safety compared with other fixed-dose combinations.

"We expect telmisartan/amlodipine to remain the clinical gold standard through 2018 because there are no other emerging agents expected to launch during this time that will have a clinical profile superior to this AIIRA/CCB combination," added Mr. Mehta.

About the Report

Hypertension: Among Fixed-Dose Combination Agents, AIIRA/CCBs Stand Out for Their Superior Efficacy and Safety is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                        Decision Resources, Inc.   Gisselle Morales                          Elizabeth Marshall   781-296-2691                              781-296-2563   gmorales@dresources.com                   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Gisselle Morales of Decision Resources, +1-781-296-2691,
gmorales@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Bristol-Myers Squibb/AstraZeneca's Onglyza Will Garner Peak Year Sales of More Than $1 Billion in the Type 2 Diabetes Drug Market

View Now